These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 23657189)
1. India remains on US trade "priority watch list" for failing to uphold international drug company patents. Arie S BMJ; 2013 May; 346():f2949. PubMed ID: 23657189 [No Abstract] [Full Text] [Related]
2. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
3. Patent watch. Harrison C Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462 [No Abstract] [Full Text] [Related]
5. US trade agreement threatens to increase drug prices and withhold safety data. Cohen D BMJ; 2013 Nov; 347():f6908. PubMed ID: 24239942 [No Abstract] [Full Text] [Related]
6. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
7. Proposed trade agreement could increase patent protection for pharmaceuticals. Eggertson L CMAJ; 2013 Jul; 185(10):E459-60. PubMed ID: 23695601 [No Abstract] [Full Text] [Related]
8. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity. Berger JM Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292 [No Abstract] [Full Text] [Related]
9. USA pressured to ease trade demands. Ahmad K Lancet; 2004 Mar; 363(9411):790. PubMed ID: 15022641 [No Abstract] [Full Text] [Related]
10. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736 [No Abstract] [Full Text] [Related]
11. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]
12. Maximizing exclusivity for drug products. French H Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117 [No Abstract] [Full Text] [Related]
13. Pills, patents, and power: state creation of gray markets as a limit on patent rights. Ghosh S Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138 [No Abstract] [Full Text] [Related]
14. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
15. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
16. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere. Baker BK PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325 [TBL] [Abstract][Full Text] [Related]
17. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS. Curti AM Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145 [No Abstract] [Full Text] [Related]
18. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
19. TRIPS, pharmaceuticals, developing countries, and the Doha "solution". Sykes AO Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299 [No Abstract] [Full Text] [Related]
20. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related] [Next] [New Search]